AUSTIN, Texas, Oct. 7, 2015 /PRNewswire/ -- Luminex Corporation
(NASDAQ: LMNX) today announced that it has received FDA clearance
for the company's ARIES® System and ARIES® HSV 1&2 Assay.
ARIES® is a sample to answer system designed to increase
laboratory efficiency, ensure result accuracy, and fit seamlessly
into today's lean laboratory environment. ARIES® uses internal
barcode scanning and other advanced features to minimize operator
errors. Two independent modules each support from one to six
cassettes, allowing for both STAT and Batch testing IVD and
MultiCode® Analyte Specific Reagents can be run simultaneously with
a common Universal Assay Protocol. An integrated touchscreen PC
eliminates the need for a separate computer, stand-alone keyboard,
and mouse; thus maximizing valuable bench space.
The company anticipates market launch in the next few weeks and
a formal introduction at the Association for Molecular Pathology
annual meeting in Austin, Texas,
November 4-7, 2015.
"We are pleased to have received a rapid clearance from the FDA
for our game-changing ARIES® System and ARIES® HSV 1 & 2 Assay
as it represents a significant milestone for Luminex and a turning
point for the molecular diagnostic industry," said Homi Shamir, President and CEO of Luminex.
"There has never been more pressure on clinical laboratories to
increase efficiency while improving the overall quality of patient
care through the delivery of accurate and timely data. To
solve this challenge, Luminex designed the ARIES sample to answer
testing platform to streamline the workflow and raise the
performance bar for all laboratory professionals no matter how big
or small the setting. To increase ARIES®' utilization and drive
rapid top-line revenue growth a key priority will be to rapidly
expand our test menu to cover the full range of disease modules.
We believe that the launch of ARIES® will increase our
potential market to cover 6,500 hospital labs, a 13 fold increase
over our current available customer base in the US."
To learn more or request a demo, visit:
http://www.luminexcorp.com/ARIES
Conference Call Information
Luminex Corporation will host a conference call to discuss the
FDA clearance of the ARIES® System and the ARIES® HSV 1&2 Assay
today, October 7, 2015, at
8:30 am ET. The conference call
will be webcast live and may be accessed at Luminex Corporation's
website at http://www.luminexcorp.com. Simply log on to the
website, go to the "About Us" section and access the "Investor
Relations link." Please go to the website at least 15 minutes prior
to the call to register, download and install any necessary
audio/video software. If you are unable to participate during the
live webcast, the call will be archived for six months on the
website using the 'replay' link.
About Herpes Simplex Virus 1 and 2 (HSV 1&2)
HSV-1 is a contagious infection, which is common and endemic
throughout the world. The virus causes lifelong infection, and
there is no cure, although treatment can reduce symptoms. It is
mainly transmitted through oral-oral contact and causes "cold
sores." HSV-2 infection is widespread and mainly sexually
transmitted. It is estimated that up to 20 million people are newly
infected with HSV-2 each year. HSV-2 causes genital herpes,
characterized by the occasional appearance of painful genital
ulcers. Prescription antivirals to treat herpes simplex include
acyclovir, famciclovir, and valacyclovir. Serious complications
occur most often in unborn babies, newborns, and people who have a
long-term illness such as cancer or HIV/AIDS, or have a weakened
immune system.
About Luminex Corporation
Luminex is committed to applying its passion for innovation
toward creating breakthrough solutions to improve health and
advance science. The company is transforming global healthcare and
life-science research through the development, manufacturing and
marketing of proprietary instruments and assays utilizing xMAP®
open-architecture multi-analyte platform, MultiCode® real-time
polymerase chain reaction (PCR), and multiplex PCR-based
technologies, that deliver cost-effective rapid results to
clinicians and researchers. Luminex's technology is commercially
available worldwide and in use in leading clinical laboratories, as
well as major pharmaceutical, diagnostic, biotechnology and life
science companies. Luminex is meeting the needs of customers in
markets as diverse as clinical diagnostics, pharmaceutical drug
discovery, biomedical research including genomic and proteomic
research, personalized medicine, biodefense research and food
safety. For further information on Luminex Corporation and the
latest advances in multiplexing using award winning technology,
please visit http://www.luminexcorp.com/.
Statements made in this release that express Luminex's or
management's intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements.
Forward- looking statements in this release include statements
regarding the available market for ARIES®, future revenue growth
anticipated for ARIES®, and the development, testing and regulatory
approval progress of our pipeline products, including ARIES®
related assays. The words "believe", "expect", "intend",
"anticipates", "confident", "will", "could", "should", and
similar expressions are intended to further identify such
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. It is important to note that the
Company's actual results or performance could differ materially
from those anticipated in such forward-looking statements. Factors
that could cause Luminex's actual results or performance to differ
materially include risks and uncertainties relating to, among
others, our ability to launch products on time, the timing of
regulatory approvals, the outcome of clinical trials as well as the
risks discussed under the heading "Risk Factors" in Luminex's
Reports on Forms 10-K and 10-Q, as filed with the Securities and
Exchange Commission. The forward looking statements contained
herein represent the judgment of Luminex as of the date of this
press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Contacts:
Luminex Investor Contact
Harriss
Currie, 512.219.8020
Sr. Vice President of Finance and CFO
hcurrie@luminexcorp.com
Luminex Media Contact
Christine Valle, 512.219.8020
Sr. Manager, Global Marketing
cvalle@luminexcorp.com
Photo - http://photos.prnewswire.com/prnh/20151006/274773
Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/luminex-corporation-receives-fda-clearance-for-aries-system-and-aries-hsv-12-assay-300155403.html
SOURCE Luminex Corporation